{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.6","upperLimit":"92.8","value":"81.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"ORR is defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). IMWG criteria (2011)- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (\\<) 5 percentage (%) plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; PR: greater than eqaul to (\\>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>= 90 percentage (%) or to \\<200 mg/24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hour.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants administered with daratumumab 16 mg/kg on Day 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 milligram (mg) on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG000","title":"Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat (ITT) population analysis set included all enrolled participants who signed the informed consent during Phase 2.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Phase 2: Percentage of Participants With Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}